Delivery Order SPE2DB24D2105-SPE2DB25FAQEB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors, with a ceiling value of $10,513.23. This firm fixed-price delivery order, with an ultimate completion date of August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The award was made without a...
- The Defense Logistics Agency awarded a $6,970.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. This award represents a non-set-aside competitive procurement, demonstrating AmerisourceBergen's continued capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a $1,525.20 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 mL pen injectors on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The contract carries no set-aside designation and...
- The Defense Logistics Agency awarded a $4.5K delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pen injectors, with a completion date of July 29, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The place of performance is located in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Zepbound 5 mg/0.5 mL pen injectors with a ceiling value of $6,706.07. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a $999,999,999.00 prime vendor agreement through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a $16,923.31 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen injectors on July 31, 2025, with completion scheduled for August 1, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract represents a firm fixed price delivery order with an ultimate completion date of August 15, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $4,275.96 to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Zepbound 5 mg/0.5 ml pen injectors. This firm fixed price delivery order, which is scheduled for completion by September 5, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, headquartered...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (tirzepatide) 2.5 mg/0.5 ml pen injectors in 0.5 ml quantities. This firm fixed-price delivery order, valued at $9,394.59, represents a competitive award with no set-aside designation and is set for completion by August 1, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, serving the federal medical...
- SPE2DB24D2105Indefinite Delivery Contract
- SPE2DB24D2105-SPE2DB25FAQEBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors at a fixed price of $8,232.97, with completion scheduled for September 8, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location. This delivery order exemplifies AmerisourceBergen's role as a critical vendor within the Defense Health Agency's pharmaceutical supply chain, supporting military and federal healthcare systems with brand-name medications and medical supplies. Zepbound (tirzepatide), a GLP-1 receptor agonist indicated for weight management, reflects the expanding scope of pharmaceutical commodities procured through federal medical supply channels. The DLA's use of AmerisourceBergen's prime vendor contract vehicle demonstrates the agency's reliance on established framework agreements to efficiently fulfill varied pharmaceutical requirements across the federal healthcare enterprise, with the broader IDC structured to enable flexible ordering of diverse therapeutic products to support military readiness and beneficiary care.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 9/5/25 |